

Robert E Bristow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3674142/publications.pdf>

Version: 2024-02-01

90
papers

7,468
citations

100601

38
h-index

66518

82
g-index

90
all docs

90
docs citations

90
times ranked

5807
citing authors

#	ARTICLE	IF	CITATIONS
1	Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 1659-1670.	0.8	33
2	Surgical Management of Gynecologic Cancers. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 69-88.	0.6	3
3	Rectosigmoid resection by gynecologic oncologists versus colorectal surgeons: as long as it catches the mouse, does the color of the cat matter?. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e51.	1.0	3
4	Population-based analysis of National Comprehensive Cancer Network (NCCN) guideline adherence for patients with anal squamous cell carcinoma in California.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1-1.	0.8	2
5	Guideline-adherent treatment, sociodemographic disparities, and cause-specific survival for endometrial carcinomas. <i>Cancer</i> , 2021, 127, 2423-2431.	2.0	9
6	Racial/Ethnic and Socioeconomic Disparities in Guideline-Adherent Treatment for Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2021, 138, 21-31.	1.2	19
7	Ambient air pollution and ovarian cancer survival in California. <i>Gynecologic Oncology</i> , 2021, 163, 155-161.	0.6	11
8	Looking at cancer health disparities in gynecologic oncology in 2020. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021, 33, 355-359.	0.9	9
9	The urban-rural gap: Disparities in ovarian cancer survival among patients treated in tertiary centers. <i>Gynecologic Oncology</i> , 2021, 163, 3-4.	0.6	4
10	Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for laryngeal cancer. <i>Laryngoscope</i> , 2020, 130, 672-678.	1.1	5
11	Incidence Rates of Gynecologic Cancers in the U.S. Active Duty Military Population. <i>Military Medicine</i> , 2020, 185, e1590-e1595.	0.4	2
12	Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPeritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS®) Society Recommendations – Part II: Postoperative management and special considerations. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2311-2323.	0.5	79
13	Ovarian cancer in California: Guideline adherence, survival, and the impact of geographic location, 1996-2014. <i>Cancer Epidemiology</i> , 2020, 69, 101825.	0.8	7
14	Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPeritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations – Part I: Preoperative and intraoperative management. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2292-2310.	0.5	98
15	Unanticipated 30-day readmission following rectosigmoid resection at the time of cytoreductive surgery in patients with advanced stage ovarian cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2020, 41, 1-6.	0.4	0
16	A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals. <i>Obstetrics and Gynecology</i> , 2020, 135, 328-339.	1.2	11
17	Contribution of Geographic Location to Disparities in Ovarian Cancer Treatment. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1318-1329.	2.3	15
18	Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018, 149, 525-530.	0.6	24

#	ARTICLE	IF	CITATIONS
19	Second primary colorectal cancer among endometrial cancer survivor: shared etiology and treatment sequelae. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 845-854.	1.2	7
20	Impact of hospital care volume on clinical outcomes of laparoscopic radical hysterectomy for cervical cancer. <i>Medicine (United States)</i> , 2018, 97, e13445.	0.4	17
21	It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 555-561.	0.6	29
22	Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study. <i>BMC Cancer</i> , 2018, 18, 800.	1.1	9
23	Cardiophrenic lymph node metastasis in low-grade serous ovarian adenocarcinoma. <i>Gynecologic Oncology Reports</i> , 2017, 19, 31-33.	0.3	0
24	Impact of community disadvantage and air pollution burden on geographic disparities of ovarian cancer survival in California. <i>Environmental Research</i> , 2017, 156, 388-393.	3.7	34
25	A Review of Thoracic and Mediastinal Cytoreductive Techniques in Advanced Ovarian Cancer: Extending the Boundaries. <i>Annals of Surgical Oncology</i> , 2017, 24, 3700-3705.	0.7	18
26	Geographic disparities in the distribution of the U.S. gynecologic oncology workforce: A Society of Gynecologic Oncology study. <i>Gynecologic Oncology Reports</i> , 2017, 22, 100-104.	0.3	28
27	Extended left upper quadrant resection during primary cytoreductive surgery for Stage IV ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 142, 378.	0.6	2
28	Surgical management of recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 142, 357-367.	0.6	23
29	Total parietal peritonectomy with en bloc pelvic resection for advanced ovarian cancer with peritoneal carcinomatosis. <i>Gynecologic Oncology</i> , 2016, 143, 688-689.	0.6	9
30	An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 303-308.	0.3	13
31	Racial/Ethnic Disparities in Gynecological Cancer Screening, Treatment, and Survival. , 2016, , 151-166.		1
32	Surgical technique of <i>en bloc</i> pelvic resection for advanced ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2015, 26, 155.	1.0	22
33	Role of aggressive surgical cytoreduction in advanced ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2015, 26, 336.	1.0	110
34	Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 139, 495-499.	0.6	23
35	Ovarian cancer in the United States: Contemporary patterns of care associated with improved survival. <i>Gynecologic Oncology</i> , 2015, 136, 11-17.	0.6	121
36	Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 121-127.	0.6	49

#	ARTICLE	IF	CITATIONS
37	Transdiaphragmatic cardiophrenic lymph node resection for Stage IV ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 762-763.	0.6	12
38	Spatial analysis of advanced-stage ovarian cancer mortality in California. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 43.e1-43.e8.	0.7	25
39	Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 468.e1-468.e9.	0.7	73
40	Impact of National Cancer Institute Comprehensive Cancer Centers on Ovarian Cancer Treatment and Survival. <i>Journal of the American College of Surgeons</i> , 2015, 220, 940-950.	0.2	94
41	A critical assessment of morcellation and its impact on gynecologic surgery and the limitations of the existing literature. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 717-724.	0.7	43
42	Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention. <i>Gynecologic Oncology</i> , 2015, 138, 694-699.	0.6	13
43	Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. <i>Gynecologic Oncology</i> , 2014, 134, 60-67.	0.6	99
44	High-volume ovarian cancer care: Survival impact and disparities in access for advanced-stage disease. <i>Gynecologic Oncology</i> , 2014, 132, 403-410.	0.6	141
45	Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 78.e1-78.e9.	0.7	41
46	Clinical commentary: Medical ethics and the ramifications of equipoise in clinical research. Is a confirmatory trial using a non-bevacizumab containing arm feasible in patients with recurrent cervical cancer?. <i>Gynecologic Oncology</i> , 2014, 134, 447-449.	0.6	6
47	The effect of ovarian imaging on the clinical interpretation of a multivariate index assay. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 65.e1-65.e11.	0.7	14
48	Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis. <i>Gynecologic Oncology</i> , 2013, 130, 493-498.	0.6	338
49	Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 581.e1-581.e8.	0.7	15
50	Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. <i>Gynecologic Oncology</i> , 2013, 128, 252-259.	0.6	115
51	Disparities in Ovarian Cancer Care Quality and Survival According to Race and Socioeconomic Status. <i>Journal of the National Cancer Institute</i> , 2013, 105, 823-832.	3.0	213
52	Adherence to Treatment Guidelines for Ovarian Cancer as a Measure of Quality Care. <i>Obstetrics and Gynecology</i> , 2013, 121, 1226-1234.	1.2	191
53	In Reply. <i>Obstetrics and Gynecology</i> , 2013, 122, 907.	1.2	1
54	A panel of biomarkers to improve specificity in presurgical assessment of adnexal masses for risk of ovarian malignancy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5573-5573.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Reply to W.R. Robinson. <i>Journal of Clinical Oncology</i> , 2012, 30, 1563-1564.	0.8	3
56	Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 4059-4067.	0.7	166
57	â€œKegel ballâ€-induced vaginal cuff dehiscence following radical abdominal hysterectomy: Laparoscopically-assisted transvaginal retrieval. <i>Gynecologic Oncology</i> , 2012, 124, 170.	0.6	0
58	Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: Redefining â€œoptimalâ€™ residual disease. <i>Gynecologic Oncology</i> , 2012, 125, 483-492.	0.6	152
59	Racial disparities in ovarian cancer surgical care: A population-based analysis. <i>Gynecologic Oncology</i> , 2011, 121, 364-368.	0.6	43
60	Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a Tertiary Gynecologic Oncology Referral Center. <i>Gynecologic Oncology</i> , 2011, 122, 319-323.	0.6	44
61	Volume-Based Trends in Parotid Surgery. <i>Laryngoscope</i> , 2010, 120, S32-S32.	1.1	0
62	The National Cancer Database report on advanced-stage epithelial ovarian cancer: Impact of hospital surgical case volume on overall survival and surgical treatment paradigm. <i>Gynecologic Oncology</i> , 2010, 118, 262-267.	0.6	193
63	Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis. <i>Gynecologic Oncology</i> , 2009, 112, 265-274.	0.6	318
64	Advanced cytoreductive surgery in gynecologic oncology. <i>Gynecologic Oncology</i> , 2009, 114, S1-S2.	0.6	10
65	Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: Operative technique and clinical outcome. <i>Gynecologic Oncology</i> , 2009, 114, 173-177.	0.6	37
66	In response to: Establishing evidence for change in ovarian cancer surgery â€” Proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis. <i>Gynecologic Oncology</i> , 2009, 115, 168-169.	0.6	4
67	Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes. <i>Gynecologic Oncology</i> , 2009, 115, 334-338.	0.6	139
68	Analysis of Contemporary Trends in Access to High-Volume Ovarian Cancer Surgical Care. <i>Annals of Surgical Oncology</i> , 2009, 16, 3422-3430.	0.7	22
69	Transverse colectomy in ovarian cancer surgical cytoreduction: Operative technique and clinical outcome. <i>Gynecologic Oncology</i> , 2008, 109, 364-369.	0.6	22
70	Neoadjuvant chemotherapy for ovarian cancer: pro versus con. <i>Women's Oncology Review</i> , 2007, 6, 27-35.	0.0	0
71	Centralization of care for patients with advanced-stage ovarian cancer. <i>Cancer</i> , 2007, 109, 1513-1522.	2.0	79
72	Prevention of adhesion formation after radical hysterectomy using a sodium hyaluronateâ€“carboxymethylcellulose (HAâ€“CMC) barrier: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2007, 104, 739-746.	0.6	32

#	ARTICLE	IF	CITATIONS
73	Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction. <i>Gynecologic Oncology</i> , 2007, 104, 480-490.	0.6	181
74	Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2007, 106, 476-481.	0.6	45
75	Surgery for ovarian cancer: how to improve survival. <i>Lancet, The</i> , 2006, 367, 1558-1560.	6.3	46
76	Impact of Surgeon Specialty on Ovarian-Conserving Surgery in Young Females with an Adnexal Mass. <i>Journal of Adolescent Health</i> , 2006, 39, 411-416.	1.2	83
77	Borderline Tumors and Other Rare Epithelial Tumors of the Ovary. , 2006, , 447-454.		0
78	Salvage cytoreductive surgery for recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2006, 103, 281-287.	0.6	61
79	Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. <i>Gynecologic Oncology</i> , 2006, 103, 709-713.	0.6	67
80	Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis. <i>Gynecologic Oncology</i> , 2006, 103, 1070-1076.	0.6	344
81	Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. <i>Gynecologic Oncology</i> , 2005, 99, 294-300.	0.6	100
82	Prevention of adhesion formation after radical oophorectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier. <i>Gynecologic Oncology</i> , 2005, 99, 301-308.	0.6	55
83	Ovarian cancer surgery in Maryland: volume-based access to care. <i>Gynecologic Oncology</i> , 2004, 93, 353-360.	0.6	37
84	Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. <i>Journal of the American College of Surgeons</i> , 2003, 197, 565-574.	0.2	107
85	Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. <i>Gynecologic Oncology</i> , 2003, 90, 519-528.	0.6	189
86	Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2002, 20, 1248-1259.	0.8	1,933
87	Recurrent micropapillary serous ovarian carcinoma. <i>Cancer</i> , 2002, 95, 791-800.	2.0	58
88	Micropapillary Serous Ovarian Carcinoma: Surgical Management and Clinical Outcome. <i>Gynecologic Oncology</i> , 2002, 86, 163-170.	0.6	36
89	A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. <i>Cancer</i> , 2000, 89, 1532-1540.	2.0	291
90	Survival Impact of Surgical Cytoreduction in Stage IV Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 1999, 72, 278-287.	0.6	288